DEUCRAVACITINIB | BRISTOL | ||
6MG | |||
No | No | ||
2033-Nov-07 | 2027-Sep-09 | ||
None | None | ||
None | No | ||
SOTYKTU is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. |
0 | 0 | 0 |
Total Other Developers | 13 |
---|
Drugs with Suitability | No |
---|
6MG | ** | ** | - | - | - |
NDA Sales Available | Total Generic Sales Available |
---|---|
Yes | 0 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com